Novato, CA — November 17, 2025 — Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to precision therapeutics for major unmet medical needs, today announced the relocation of its corporate headquarters to the campus of the Buck Institute for Research on Aging in Novato, California.
 

Lighthouse’s lead program, LHP588, is an orally bioavailable small-molecule gingipain inhibitor currently in a 300-patient Phase 2 study for the treatment of Porphyromonas gingivalis-positive Alzheimer’s disease. This study is supported by a $49.2 million grant from the National Institute on Aging.   The Buck Institute is the world’s first independent biomedical research institute solely focused on understanding the biology of aging and its impact on disease, with a mission “to create a world where everyone can have healthy minds and healthy bodies at every age.”

“We are thrilled to position our headquarters within the Buck Institute campus,” said Casey Lynch, CEO of Lighthouse Pharmaceuticals. “This relocation signals our commitment to accelerating medicines for age-associated diseases, and to working in partnership with a premier longevity-science community. Together, we can better fulfill our mission of changing the way we treat disease.”

Eric Verdin, President and CEO of the Buck Institute added, “The Buck has always championed collaboration across disciplines to end age-related disease. Hosting Lighthouse Pharmaceuticals on our campus amplifies our collective potential to move fundamental insights into clinical reality.”

​

About Lighthouse Pharmaceuticals
Lighthouse Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering precision medicine approaches to major unmet medical needs. Lighthouse Pharmaceuticals develops small-molecule therapeutics, leveraging translational insights and extensive clinical experience to address chronic degenerative and inflammatory disorders, with a lead program focused on Alzheimer’s disease. www.lighthousepharma.com

​

About the Buck Institute for Research on Aging
The Buck Institute for Research on Aging is an independent biomedical research institute located in Novato, California. Its mission is to end the threat of age-related disease for current and future generations by understanding the biology of aging and translating that knowledge into therapies. https://www.buckinstitute.org/

​

 

Information in this release refers to National Institute on Aging of the National Institutes of Health under Award Number R01AG088524. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.